Emergent BioSolutions (NSYE:EBS) announced today that it plans to put its over-the-counter Narcan nasal spray on U.S. shelves next month.
FDA approved the over-the-counter Narcan spray in May. Approval enabled direct-to-consumer sales in places like drug stores, convenience stores and more. The FDA nod came about six weeks after an agency committee voted unanimously in favor of OTC use. It marked the first approval for a naloxone product for use without a prescription.
The naloxone HCl nasal spray (4 mg) will become available on shelves nationwide and online beginning in September. Over-the-counter (OTC) Narcan access enables wide accessibility to a tool that combats opioid emergencies. It can reverse the effects of opioids, including fentanyl.
Emergent BioSolutions expects to make the treatment available at leading mass drug, grocery and online retailers. The company said the Manufacturer’s Suggested Retail Price comes in at $44.99 per carton, or roughly $22.50 per dose. Emergent BioSolutions said in a news release that it works with partners to help maintain access and affordability. However, individual retailers determine the price of the product.
The company said in an effort to broaden distribution and maintain affordability, it lowered the public interest price to $41 per carton. That goes into effect Aug. 31, 2023, Emergent BioSolutions said. The company recently changed its strategy, including enacting 400 job cuts, to tighten its focus on Narcan.
“A steadfast commitment to expanding access to naloxone has always been at the forefront of our work to help save lives and we’re proud to bring Narcan nasal spray to many, many more places,” said Paul Williams, SVP, products business at Emergent BioSolutions. “Expanding availability to online and in-store shelves, increasing awareness and education to reduce stigma, and calling on the public to be prepared, is additive to the current work Emergent does every single day to stem the tide of this public health threat.
“On the eve of International Overdose Awareness Day, we stand by our ongoing efforts with advocates, patients, customers and policy stakeholders to implement efforts that enhance naloxone distribution to all those in need.”